Latest Content

Submit to our writing contest for the opportunity to win publication in Psychiatric Times and a $500 prize!

Johnson & Johnson's Caplyta gains FDA approval as an adjunctive treatment for major depressive disorder, offering hope for improved patient outcomes.

Explore the intersection of AI and mental health, specifically the implications of technology on clinician well-being and ethical psychiatry.

Answer our poll!

Discover how combining transcranial magnetic stimulation and ketamine therapy revolutionizes treatment for complex conditions like depression and pain.

Axsome Therapeutics advances AXS-05 for Alzheimer disease agitation, showing significant improvement in clinical trials and addressing critical patient needs.

Explore the intriguing connection between fava beans, dopamine, and mental health through a patient's unique journey with favism and bipolar disorder.

AI chatbots change mental health care, offering 24/7 support while posing unique challenges for human therapists in an evolving landscape.

The 2026 NCCHC Standards revolutionize mental health care in correctional facilities, emphasizing ethical practices, interdisciplinary collaboration, and patient dignity.

Explore the intersection of psychiatry and social issues, addressing xenophobia and promoting understanding among diverse communities for a better future.

Halloween poses unique challenges for individuals with mental health disorders, but strategies exist to help them navigate the spooky season safely.

Explore the psychological meanings behind Halloween symbols, from ghosts to jack-o'-lanterns, and uncover their deeper significance in our lives.

Check out the pipeline updates from October!